CytomX Therapeutics
在场
CytomX Therapeutics 是一家在股票代码 CTMX (US) 下上市的公司。
高管
查看带有其 16 名主要高管的组织结构图
CytomX Therapeutics 搜索最多的简介
- Sean McCarthy, President, Chief Executive Officer and Chairman of ...
- Matthew Young, Director
- Alan Ashworth, Director
高管在CytomX Therapeutics变化
- Chris Ogden 曾任 Senior Vice President, Finance and Accounting, 现升职为 Chief Financial Officer (新闻发布的2024六月18号).
- Zhen Su已作为Director加入公司 (新闻发布的2024三月22号).
创建提醒
跟踪 CytomX Therapeutics 的高管变动
生物技术
CytomX Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
- Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
生物技术 行业的其他推荐联系人
消息
CytomX Therapeutics 的最新新闻稿
- CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences | CytomX Therapeutics, Inc.
- CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022 | CytomX Therapeutics, Inc.
- CytomX Therapeutics Provides Strategic Update | CytomX Therapeutics, Inc.
- CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer | CytomX Therapeutics, Inc.
- CytomX Therapeutics Announces New Employment Inducement Grants | CytomX Therapeutics, Inc.
- CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference | CytomX Therapeutics, Inc.
- CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors | CytomX Therapeutics, Inc.
- CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update | CytomX Therapeutics, Inc.
- CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022 | CytomX Therapeutics, Inc.
- Press Releases | CytomX Therapeutics, Inc.
- View more press releases Close
通过电子邮件
